

Espen Molden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/569644/publications.pdf>

Version: 2024-02-01

84
papers

4,413
citations

218381

26
h-index

138251

58
g-index

94
all docs

94
docs citations

94
times ranked

6472
citing authors

#	ARTICLE	IF	CITATIONS
1	Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. <i>Nature Genetics</i> , 2018, 50, 381-389.	9.4	1,332
2	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	13.7	929
3	The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 1049-1053.	0.8	149
4	Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. <i>American Journal of Psychiatry</i> , 2018, 175, 463-470.	4.0	136
5	Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. <i>Lancet Psychiatry</i> , 2019, 6, 418-426.	3.7	113
6	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	1.7	107
7	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure. <i>JAMA Psychiatry</i> , 2021, 78, 270.	6.0	91
8	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. <i>Biological Psychiatry</i> , 2022, 91, 102-117.	0.7	61
9	Metabolism of Quetiapine by CYP3A4 and CYP3A5 in Presence or Absence of Cytochrome B ₅ . <i>Drug Metabolism and Disposition</i> , 2009, 37, 254-258.	1.7	58
10	Effect of Clinical Geriatric Assessments and Collaborative Medication Reviews by Geriatrician and Family Physician for Improving Health-Related Quality of Life in Home-Dwelling Older Patients Receiving Polypharmacy. <i>JAMA Internal Medicine</i> , 2020, 180, 181.	2.6	49
11	Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 333-342.	2.3	46
12	Genetic Association Between Schizophrenia and Cortical Brain Surface Area and Thickness. <i>JAMA Psychiatry</i> , 2021, 78, 1020.	6.0	43
13	Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 933-940.	0.8	40
14	Pharmacokinetic Variability of Quetiapine and the Active Metabolite N-desalkylquetiapine in Psychiatric Patients. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 222-226.	1.0	39
15	Desacetyl-Diltiazem Displays Several-fold Higher Affinity to CYP2D6 Compared with CYP3A4. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1-3.	1.7	38
16	Simvastatin-Associated Rhabdomyolysis After Coadministration of Macrolide Antibiotics in Two Patients. <i>Pharmacotherapy</i> , 2007, 27, 603-607.	1.2	38
17	Serum Concentrations of Antidepressants in The Elderly. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 25-30.	1.0	38
18	Risk Management of Simvastatin or Atorvastatin Interactions with CYP3A4 Inhibitors. <i>Drug Safety</i> , 2008, 31, 587-596.	1.4	37

#	ARTICLE	IF	CITATIONS
19	OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. <i>Biochemical Pharmacology</i> , 2011, 82, 1219-1226.	2.0	35
20	CYP2D6 is involved in O-demethylation of diltiazem. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 575-579.	0.8	34
21	Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 119-125.	0.8	32
22	Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 127-134.	1.0	32
23	Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients—a genome-wide association study adjusting for smoking habits. <i>Translational Psychiatry</i> , 2020, 10, 198.	2.4	32
24	Individual variability in clinical effect and tolerability of opioid analgesics — Importance of drug interactions and pharmacogenetics. <i>Scandinavian Journal of Pain</i> , 2017, 17, 193-200.	0.5	31
25	Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 550-555.	1.0	31
26	4β-Hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 269-276.	1.1	28
27	Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015. <i>Epilepsy Research</i> , 2018, 139, 35-42.	0.8	28
28	Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 194-201.	1.1	28
29	Serum Concentrations of Risperidone and Aripiprazole in Subgroups Encoding CYP2D6 Intermediate Metabolizer Phenotype. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 80-85.	1.0	26
30	High-performance liquid chromatography–mass spectrometry analysis of diltiazem and 11 of its phase I metabolites in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 33, 275-285.	1.4	24
31	Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 463-468.	1.0	24
32	Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1211-1221.	1.5	24
33	Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 750-758.	2.3	22
34	Primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low clearance. <i>Drug Metabolism and Disposition</i> , 2021, , DMD-AR-2020-000340.	1.7	22
35	Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 279-285.	0.7	21
36	Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. <i>Drugs and Aging</i> , 2019, 36, 65-71.	1.3	21

#	ARTICLE	IF	CITATIONS
37	Evaluation of Organic Anion-Transporting Polypeptide 1B1 and CYP3A4 Activities in Primary Human Hepatocytes and HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor System. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 145-156.	1.3	20
38	Impact of Genetic Variability in CYP2D6, CYP3A5, and ABCB1 on Serum Concentrations of Quetiapine and N-desalkylquetiapine in Psychiatric Patients. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 256-261.	1.0	19
39	The CYP3A biomarker 4 β -hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1457-1465.	1.1	19
40	Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. <i>PLoS ONE</i> , 2019, 14, e0220071.	1.1	19
41	European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 140-147.	0.7	19
42	4 β -Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2398-2405.	1.1	18
43	Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1243-1252.	1.1	18
44	Severity and Management of Drug-Drug Interactions in Acute Geriatric Patients. <i>Drugs and Aging</i> , 2013, 30, 721-727.	1.3	17
45	Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 570-576.	0.7	17
46	Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1384-1389.	1.7	17
47	CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry. <i>Frontiers in Pharmacology</i> , 2021, 12, 650750.	1.6	17
48	Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 43-50.	0.7	17
49	Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study. <i>CNS Drugs</i> , 2017, 31, 991-997.	2.7	16
50	Reduction in N-Desmethylclozapine Level Is Determined by Daily Dose But Not Serum Concentration of Valproic Acid: Indications of a Presystemic Interaction Mechanism. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 503-508.	1.0	16
51	The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 137-144.	0.7	16
52	The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 611-615.	1.1	14
53	Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 546-549.	1.0	14
54	Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitro. <i>Drug Metabolism and Disposition</i> , 2000, 28, 107-9.	1.7	14

#	ARTICLE	IF	CITATIONS
55	Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 41-49.	0.8	13
56	Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction – a prospective observational study. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 673-683.	0.8	12
57	Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders. <i>Schizophrenia Research</i> , 2021, 228, 590-596.	1.1	12
58	Effect of medicines management versus standard care on readmissions in multimorbid patients: a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e041558.	0.8	12
59	In Vitro Apixaban Removal By CytoSorb Whole Blood Adsorber: An Experimental Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 1636-1644.	0.6	12
60	The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1165-1174.	2.3	12
61	Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 470-475.	1.2	11
62	Cooperation between geriatricians and general practitioners for improved pharmacotherapy in home-dwelling elderly people receiving polypharmacy – the COOP Study: study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2017, 18, 158.	0.7	11
63	Effect of teaching and checklist implementation on accuracy of medication history recording at hospital admission. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 20-24.	1.0	10
64	Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs – A study based on blood sample analyses from 24,239 patients. <i>European Neuropsychopharmacology</i> , 2020, 37, 64-69.	0.3	10
65	Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 525-530.	0.8	9
66	Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite 4β-Hydroxycholesterol – an Interaction Study in Healthy Volunteers. <i>AAPS Journal</i> , 2019, 21, 58.	2.2	9
67	Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1289-1299.	0.8	9
68	Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00430.	1.1	8
69	Use of Antidepressants in Older People during a 10-Year Period: An Observational Study on Prescribed Doses and Serum Levels. <i>Drugs and Aging</i> , 2020, 37, 691-701.	1.3	8
70	Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 281-285.	0.7	8
71	Variability in Cytochrome P450-Mediated Metabolism of Cardiovascular Drugs: Clinical Implications and Practical Attempts to Avoid Potential Problems. <i>Cardiology</i> , 2004, 4, 55-79.	0.3	6
72	Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine. <i>NPJ Schizophrenia</i> , 2020, 6, 17.	2.0	6

#	ARTICLE	IF	CITATIONS
73	Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. <i>CNS Drugs</i> , 2021, 35, 999-1008.	2.7	6
74	Bodyweightâ€ adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1350-1352.	1.1	5
75	Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulationsâ€ an observational study using blood samples from 1223 patients. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1201-1208.	0.8	5
76	Association between statin use and physical performance in home-dwelling older patients receiving polypharmacy: cross-sectional study. <i>BMC Geriatrics</i> , 2022, 22, 242.	1.1	5
77	Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1475-1486.	1.6	4
78	Gjestad <i>et al.</i> reply to â€ Was 4Î²â€ hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?â€™ by Neuhoff and Tucker. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1624-1625.	1.1	3
79	Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulationâ€ an observational study including 2044 patients. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 215-221.	0.8	3
80	Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 396-399.	0.7	3
81	Celecoxib is often combined with cytochrome P450 2D6 substrates in general clinical practice. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 93-93.	2.3	2
82	Recovery of CYP3A Phenotype after Kidney Transplantation. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1260-1265.	1.7	1
83	Effects of a Novel <i>UGT2B</i> Haplotype and <i>UGT1A4*3</i> Allele Variants on Glucuronidation of Clozapine <i>In vivo</i>. <i>Current Drug Metabolism</i> , 2022, 23, 66-72.	0.7	1
84	Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy. <i>Drugs and Aging</i> , 2020, 37, 425-433.	1.3	0